Overview
- The U.S. Solicitor General urged the Supreme Court to hear Bayer’s appeal of a Missouri case that awarded $1.25 million to plaintiff John Durnell.
- The government’s brief points to EPA conclusions that glyphosate is unlikely to be carcinogenic and to federally approved labels without cancer warnings.
- Bayer shares rose about 13–15% to their highest level since early 2024 after the filing increased the likelihood of high-court review.
- The company still faces roughly 65,000–67,000 U.S. lawsuits, having already paid about $10 billion in settlements and carrying near €7 billion in related reserves.
- If the Court grants review, analysts forecast a ruling by mid‑2026, following two failed Bayer attempts in 2022 and the firm’s move to remove glyphosate from U.S. consumer products.